The aim of this study is to determine ifNB-001 (an investigational drug that is not approved by the FDA) is effective, safe, and well tolerated intreating children and adolescents with 22q11DS and anxiety, inattention, and/or autism. The study will take place over a 21-week period with routine telemedicine check-ins, home health nurse visits, and behavioral questionnaires. Except for the first visit which will be in-person at the CHOP Philadelphia campus, all other study visits will be done at the patient's home by a study nurse.

We want to study brain responses during simulated driving and are currently looking for participants 12-17 years old or those who have had brain surgery. To do so, we'll have eligible participants come to CHOP for some non-invasive (safe) brain scans and drive using a simulator. If you are interested in learning more about the study, please contact Victoria Kaufman at kaufmanv@chop.edu or 267-425-4150.